Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ZUMA-22 in relapsed/refractory follicular lymphoma
jRCT2063230096Phase 3Active, not recruiting
- Sponsor
- Gilead Sciences
- Start
- Feb 2024
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
01
Overview
Phase 3, randomised, open-label trial in follicular lymphoma (FL) comparing Axicabtagene ciloleucel with Standard of care therapy (2 arms). Primary endpoint: Progression-free survival. Started Feb 2024; status: active, not recruiting.
02
Drugs
axicabtagene ciloleucel
03
Conditions
follicular lymphoma (FL)
Beyond the preview
Go deeper on jRCT2063230096.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2063230096.